Skip to main content
Premium Trial:

Request an Annual Quote

Roche Epstein-Barr Virus Quantitative Test Receives FDA Clearance

NEW YORK – Roche announced Wednesday its Cobas Epstein-Barr Virus test was authorized for use by the US Food and Drug Administration.

The quantitative test uses dual target technology to help clinicians monitor transplant patients who are at risk of complications from infections or reactivations of the virus. The PCR viral load test runs on Roche's Cobas 6800 and Cobas 8800 Systems and can be run simultaneously with other virology tests, the company said. It has been calibrated to the World Health Organization International Standard, meaning results are reported in international measures. The test's limit of detection is 18.8 IU per milliliter. 

Roche's test previously received breakthrough device designation from the FDA and obtained CE marking last year. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.